Obstetrics & Gynaecology Search

Obstetrics & Gynaecology

Obstetrics & Gynaecology

Home News Diseases Conferences Special Reports Multimedia

OVARIAN MASS

Ovarian cysts are typically noted after clinical screening, or as a result of exam for a suspected pelvic mass, or an incidental finding in investigations done for other reasons.
Most ovarian masses manifest with few or mild nonspecific symptoms.
Ovarian masses in women of reproductive age are mostly benign but the risk of malignancy increases with age.
Ovarian cysts in the prepubertal patients especially after the first week of life are abnormal and likely to be neoplastic. In adolescent patients, majority of ovarian masses are functional cysts.

Ovarian%20mass Treatment

Treatment

Pharmacotherapy

Combination Oral Contraceptives (OCs)

Combination OCs do not provide an advantage in the treatment of functional ovarian cysts when compared with expectant management
- Studies suggested that expectant management is as effective as hormonal treatment for the resolution of functional ovarian cysts
Patients may be offered OCs if they are seeking contraception
Estrogen/progestogen therapy may be useful in patients with anovulatory cycles who need OCs to induce the next period
Many combination OCs are available. Please see the latest MIMS for specific prescribing information

Gangliosides and cognition: An appraisal of the evidence

01 Sep 2018

Gangliosides and docosahexaenoic acid (DHA) play critical roles in early childhood brain development.

SNPs likely to improve breast cancer risk prediction

Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Integrate genetic testing into local routine oncology care

Dr Joslyn Ngu, 04 Dec 2017

Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya.